Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice

The emergence of new immune-evasive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and subvariants outpaces the development of vaccines specific against the dominant circulating strains. In terms of the only accepted immune correlate of protection, the inactivated whole-virion vaccine using wild-type SARS-CoV-2 spike induces a much lower serum neutralizing antibody titre against the Omicron subvariants. Since the inactivated vaccine given intramuscularly is one of the most commonly used coronavirus disease 2019 (COVID-19) vaccines in developing regions, we tested the hypothesis that intranasal boosting after intramuscular priming would provide a broader level of protection. Here, we showed that one or two intranasal boosts with the Fc-linked trimeric spike receptor-binding domain from wild-type SARS-CoV-2 can induce significantly higher serum neutralizing antibodies against wild-type SARS-CoV-2 and the Omicron subvariants, including BA.5.2 and XBB.1, with a lower titre in the bronchoalveolar lavage of vaccinated Balb/c mice than vaccination with four intramuscular doses of inactivated whole virion vaccine. The intranasally vaccinated K18-hACE2-transgenic mice also had a significantly lower nasal turbinate viral load, suggesting a better protection of the upper airway, which is the predilected site of infection by Omicron subvariants. This intramuscular priming and intranasal boosting approach that achieves broader cross-protection against Omicron variants and subvariants may lengthen the interval required for changing the vaccine immunogen from months to years.

[1]  K. To,et al.  Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines , 2022, The Lancet Microbe.

[2]  Haiwei Zhang,et al.  An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response , 2022, Frontiers in Immunology.

[3]  K. To,et al.  Evolution and Control of COVID-19 Epidemic in Hong Kong , 2022, Viruses.

[4]  S. Malaivijitnond,et al.  A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques , 2022, Frontiers in Plant Science.

[5]  Shibo Jiang,et al.  Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses , 2022, Nature Reviews Immunology.

[6]  Jie Zhou,et al.  Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines , 2022, Journal of medical virology.

[7]  Tao Li,et al.  An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants , 2022, Signal Transduction and Targeted Therapy.

[8]  C. Ke,et al.  Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants , 2022, Vaccines.

[9]  Jian-Piao Cai,et al.  Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2 , 2022, Cell Reports Medicine.

[10]  K. To,et al.  Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong , 2022, Nature Communications.

[11]  K. To,et al.  Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters , 2022, Science.

[12]  D. Lung,et al.  Decreased Antibiotic Consumption Coincided with Reduction in Bacteremia Caused by Bacterial Species with Respiratory Transmission Potential during the COVID-19 Pandemic , 2022, Antibiotics.

[13]  M. Davenport,et al.  Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? , 2022, Nature Reviews Immunology.

[14]  O. Tsang,et al.  Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines , 2022, eBioMedicine.

[15]  Wanbo Tai,et al.  Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant , 2022, bioRxiv.

[16]  K. To,et al.  Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2 , 2022, The Lancet Microbe.

[17]  Jie Zhou,et al.  Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant , 2022, Viruses.

[18]  Paul J. Birrell,et al.  Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines , 2022, Nature Medicine.

[19]  Liyuan Liu,et al.  Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.

[20]  L. Poon,et al.  SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo , 2022, Nature.

[21]  K. To,et al.  Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron , 2021, Nature.

[22]  O. Tsang,et al.  Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients , 2021, medRxiv.

[23]  K. To,et al.  Emerging SARS-CoV-2 variants expand species tropism to murines , 2021, EBioMedicine.

[24]  J. Yee,et al.  Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 , 2021, Vaccine.

[25]  Wenbin Zhao,et al.  Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 , 2021, Viruses.

[26]  K. To,et al.  Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Jun-Gu Guo,et al.  Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist , 2021, Journal of medicinal chemistry.

[28]  M. Beltramello,et al.  SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.

[29]  R. W. Yung,et al.  Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results. , 2021, Hong Kong medical journal = Xianggang yi xue za zhi.

[30]  Jian-Piao Cai,et al.  Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity , 2021, Science Advances.

[31]  Yan Li,et al.  Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice , 2021, Cellular & molecular immunology.

[32]  Ronald A. Li,et al.  Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 , 2021, Nature.

[33]  K. To,et al.  Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic , 2021, Emerging microbes & infections.

[34]  D. Qu,et al.  RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response , 2020, Signal Transduction and Targeted Therapy.

[35]  O. Tsang,et al.  Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.

[36]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[37]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[38]  Shibo Jiang,et al.  Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity , 2009, Virology.

[39]  C. Alving,et al.  Human Immunodeficiency Virus Type 1 Gag p24 Alters the Composition of Immunoproteasomes and Affects Antigen Presentation , 2009, Journal of Virology.

[40]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[41]  Shibo Jiang,et al.  Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein , 2006, The Journal of Immunology.

[42]  M. Lotze,et al.  Complementary Dendritic Cell–activating Function of CD8+ and CD4+ T Cells , 2002, The Journal of experimental medicine.